Marinus Pharmaceuticals Aktie [WKN DE: A12CGZ / ISIN: US56854Q1013]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Marinus Pharmaceuticals Inc

18.07.24		Marinus Pharma Says Ganaxolone To Treat Seizures Associated With CDD Approved In China (RTTNews)
17.06.24		Marinus Pharma Says Phase 3 Trial Of IV Ganaxolone In RSE Meets First Co-primary Endpoint (RTTNews)
15.04.24		Marinus Pharma Says RAISE Trial Did Not Meet The Early Stopping Criteria; Stock Dips In Pre-market (RTTNews)
26.04.23		Did You Catch These Biotech High-Flyers Before They Hit New Highs Yesterday? (RTTNews)
22.03.23		Marinus : FDA Grants Orphan Drug Designation To Ganaxolone For Lennox-Gastaut Syndrome Treatment (RTTNews)
17.11.22		Marinus Pharma Names CEO Scott Braunstein As Chairman (RTTNews)
08.11.22		Pre-market Movers: NRBO, HIMS, OCUP, TRIP, TTWO… (RTTNews)
22.03.22		CLRB To Report WM Trial Data In 2H, DICE On Watch, URGN Sees 46%-67% Revenue Growth In 2022 (RTTNews)
28.02.22		Biotech Stocks Facing FDA Decision In March 2022 (RTTNews)
10.02.22		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Businesswire)
03.02.22		Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update (Businesswire)
14.01.22		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Businesswire)
05.01.22		Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference (Businesswire)
27.12.21		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Businesswire)
03.12.21		Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting (Businesswire)
01.07.21		Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D. (Businesswire)
22.06.21		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.06.21		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
11.06.21		Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences (Businesswire)
17.05.21		Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results (Businesswire)
13.05.21		Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call (Businesswire)
07.05.21		Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021 (Businesswire)
28.04.21		Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences (Businesswire)
12.04.21		Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
12.04.21		Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments (Businesswire)
24.03.21		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
24.03.21		Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors (Businesswire)
09.03.21		Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results (Businesswire)
23.02.21		Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization (Businesswire)
17.02.21		Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences (Businesswire)
12.02.21		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
10.02.21		Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021 (Businesswire)
26.01.21		Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus (Businesswire)
13.01.21		Stock Alert: Marinus Pharmaceuticals Climbs 11% (RTTNews)
06.01.21		Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference (Businesswire)
21.12.20		Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index (Businesswire)
08.12.20		Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock (Businesswire)
08.12.20		Pre-market Movers In Healthcare Sector: NURO, CGIX, MRNS, ARCT… (RTTNews)
07.12.20		Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock (Businesswire)
07.12.20		Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update (Businesswire)
07.12.20		Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder (Businesswire)
04.12.20		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.12.20		Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020 (Businesswire)
23.11.20		Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting (Businesswire)
10.11.20		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
09.11.20		Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results (Businesswire)
09.11.20		Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer (Businesswire)
20.10.20		Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020 (Businesswire)
19.10.20		Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences (Businesswire)
14.10.20		Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 14:59
Kaufwert:	EUR
	Hinzufügen Speichern